Face-to-face with Canada’s planned accessibility legislation
Last May we asked Canadians affected by MS what independence means to them. The resounding answer was that having the ability to work,…
Late-breaking ECTRIMS 2016 session unveils new biomarkers, real-world treatment comparisons, and clinical trial results
Each year ECTRIMS ends with a bang as late-breaking research news is presented first thing in the morning. Presenters at the late-breaking news…
Spending time: My MS journey
By François Marcotte When I was 20, my life was like the song Hier Encore by Charles Aznavour which, roughly translated means that…
Poster session at ECTRIMS 2016 covers the gamut of wellness and symptom management research
While platform presentations tend to get all the glory and attention at scientific conferences, I like to think of poster presentations as the…
MS hits close to home
Interview with Kate and Sam I recently sat down with two of our #MSBike ambassadors, who happen to both be affected by multiple…
Targeting remyelination: A new chapter in MS therapies?
Ever since disease-modifying therapies emerged onto the scene in the mid-1990s, suppression of damaging inflammation and prevention of the entry of harmful immune…
What can imaging tell us about the course of MS disease?
This morning at ECTRIMS we heard from several researchers and clinicians about the use of imaging as a tool to predict disease outcomes…
Multi-million dollar grants announced at ECTRIMS by the International Progressive MS Alliance marks major milestone in progressive MS research
How quickly time flies. A little over a year ago, the MS Society announced the recipients of the International Progressive MS Alliance planning…
World’s brightest minds gather in London for largest MS conference
The MS Society of Canada’s research team has arrived in the vibrant city of London, England to attend the 32nd Congress of the…
What is MS?
Canada has one of the highest rates of multiple sclerosis (MS) in the world, with an estimated 77,000 Canadians living with the disease. While it is most often diagnosed in young adults aged 20 to 49, younger children and older adults are also diagnosed with the disease.